3/12
04:42 pm
lyel
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results [Yahoo! Finance]
High
Report
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results [Yahoo! Finance]
3/12
04:05 pm
lyel
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
High
Report
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
3/9
09:03 am
lyel
Lyell Immunopharma (LYEL) is now covered by Citizens Jmp. They set a "market outperform" rating and a $34.00 price target on the stock.
High
Report
Lyell Immunopharma (LYEL) is now covered by Citizens Jmp. They set a "market outperform" rating and a $34.00 price target on the stock.
3/9
08:25 am
lyel
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer [Yahoo! Finance]
High
Report
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer [Yahoo! Finance]
3/9
08:00 am
lyel
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
High
Report
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
3/6
04:58 pm
lyel
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
High
Report
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
2/26
04:22 pm
lyel
Keros Therapeutics Appoints Charles Newton to its Board of Directors [Yahoo! Finance]
Medium
Report
Keros Therapeutics Appoints Charles Newton to its Board of Directors [Yahoo! Finance]
2/23
08:00 am
lyel
Lyell Immunopharma Announces Participation in March Investor Conferences
Medium
Report
Lyell Immunopharma Announces Participation in March Investor Conferences
2/12
07:30 am
lyel
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
Medium
Report
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
12/24
08:31 am
lyel
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]
Low
Report
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]